North Central London
Joint Formulary
 
back
8 Malignant disease and immunosuppression

The formulary for systemic anti-cancer treatments should be viewed alongside the 'National Cancer Drugs Fund list'

https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/

08-02-02 Corticosteroids and other immunosuppressants

Antithymocyte immunoglobulin - rabbit Thymoglobuline®
Restricted

Provider notes

  • RFL:
    • Resricted to renal team for the treatment of transplant rejection
Link  NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  HCD
Basiliximab
Restricted

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but service is not offered at NMUH.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • Prior funding required for treatment of lymphoma with radiolabelled basiliximab Approved for Renal transplant patients.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Ciclosporin Capimune®
Formulary

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

View adult BNF  View SPC online  View childrens BNF
Ciclosporin Capsorin®
Formulary

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

View adult BNF  View SPC online  View childrens BNF
Ciclosporin Deximune®
Formulary

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Deximune is the first-line choice for all new liver transplant patients. 
    • Previous liver tranplant patients must be maintained on the same brand (usually Neoral).  Brand are not interchangeable.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

View adult BNF  View SPC online  View childrens BNF
Ciclosporin Neoral®
Formulary

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Restricted to Consultant use only.
  • RFL:
    • Patients must be maintained on the same brand
    • 1st choice for renal transplant
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

View adult BNF  View SPC online  View childrens BNF
Ciclosporin Sandimmun®
Formulary

NOTE: There is more than one monograph for Ciclosporin, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary

View adult BNF  View SPC online  View childrens BNF
Sirolimus
Formulary

GP-Red Red For all new transplants, except liver

GP-Grey Red Existing transplants and liver transplants

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • See links below
    • Not to be intiated at NMUH. For continuation of immunosuppressant therapy
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
 

View adult BNF  View SPC online  View childrens BNF  HCD
Tacrolimus Adoport®
Formulary

GP-Red Red For all new transplants, except liver

GP-Grey Red Existing transplants and liver transplants

Provider notes

  • NMUH:
    • Not to be intiated at NMUH. For continuation of immunosuppressant therapy
  • RFL:
    • Preferred brand of tacrolimus for all new liver transplant patients
    • Preferred brand of tacrolimus for all new kidney transplant patients
    • Brands are not interchangeable, patients must be maintained on the same brand
    • See individual transplant policies for dosing information
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
 

View adult BNF  View SPC online  View childrens BNF
Tacrolimus Modigraf®
Formulary

GP-Red Red For all new transplants, except liver

GP-Grey Red Existing transplants and liver transplants

Provider notes

  • NMUH:
    • Not to be intiated at NMUH. For continuation of immunosuppressant therapy
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
 

View adult BNF  View SPC online  View childrens BNF
Tacrolimus Prograf®
Restricted

GP-Red Red For all new transplants, except liver

GP-Grey Red Existing transplants and liver transplants

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Historic transplant patients
    • Transplant patients must be maintained on the same brand
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Link  NMUH: Trust Therapeutic Drug Monitoring Guidelines
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF
Tacrolimus Vivadex®
Formulary

GP-Red Red For all new transplants, except liver

GP-Grey Red Existing transplants and liver transplants

Provider notes

  • NMUH:
    • Not to be intiated at NMUH. For continuation of immunosuppressant therapy
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
 

View adult BNF  View SPC online  View childrens BNF
Tacrolimus modified release Advagraf®
Formulary

GP-Red Red For all new transplants, except liver

GP-Grey Red Existing transplants and liver transplants

Provider notes

  • NMUH:
    • Not to be intiated at NMUH. For continuation of immunosuppressant therapy
  • RFL:
    • Envarsus is now the preferred modified release preparation
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
 

View adult BNF  View SPC online  View childrens BNF
Tacrolimus modified release Envarsus®
Formulary

GP-Red Red For all new transplants, except liver

GP-Grey Red Existing transplants and liver transplants

Provider notes

  • NMUH:
    • Not to be intiated at NMUH. For continuation of immunosuppressant therapy
  • RFL:
    • Approved for immunosuppression in liver and renal transplants for patient in whom Advagraf would otherwise be indicated. For RFL only (approved by DTC in May-16, ratified by JFC in June-16)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
 

View adult BNF  View SPC online  View childrens BNF
Belatacept
Non Formulary
Link  NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
 

View adult BNF  View SPC online  View childrens BNF  HCD
Everolimus Certican®
Non Formulary

DO NOT CONFUSE Afinitor®, Votubia AND Certican AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Link  NICE TA348 (not recommended): Everolimus for preventing organ rejection in liver transplantation
Link  NICE TA481 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482 (not recommended as initial treatment): Immunosuppressive therapy for kidney transplant in children and young people
 

View adult BNF  View SPC online  View childrens BNF  HCD